Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Third Quarter 2009 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., Nov. 3, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
October 15, 2009 06:00 ET | Source: Oxigene, Inc.

OXiGENE to Acquire VaxGen in a Stock-for-Stock Merger

Acquisition to Add Approximately $33 Million in Cash to OXiGENE's Balance Sheet Conference Call Today at 9:00 AM Eastern SOUTH SAN FRANCISCO, Calif., Oct. 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE,...
October 12, 2009 08:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Data Presentation At 2009 AACR-EORTC-NCI Conference

WALTHAM, Mass., Oct. 12, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
October 08, 2009 08:00 ET | Source: Oxigene, Inc.

Oxigene Announces Management Changes

SOUTH SAN FRANCISCO, Calif., Oct. 8, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
July 30, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Reports Second Quarter 2009 Financial Results; Company Continues to Achieve Pipeline Progress With Strengthened Cash Position

SOUTH SAN FRANCISCO, Calif., July 30, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
July 24, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Second Quarter 2009 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., July 24, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer...
July 21, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Closing of Registered Direct Offering

SOUTH SAN FRANCISCO, Calif., July 21, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer...
July 15, 2009 09:00 ET | Source: Oxigene, Inc.

OXiGENE to Raise $10 Million in Registered Direct Offering

WALTHAM, Mass., July 15, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye...
July 06, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Announces Agreement to Acquire Symphony ViDA, Including More Than $12 Million in Unrestricted Cash and All Rights to OXi4503 and ZYBRESTAT for Ophthalmology

SOUTH SAN FRANCISCO, Calif., July 6, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (Stockholm:OXGN), a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and...
June 25, 2009 02:00 ET | Source: Oxigene, Inc.

OXiGENE Initiates Phase 2 Trial of ZYBRESTAT for Ophthalmology

SOUTH SAN FRANCISCO, Calif., June 25, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced that...